Director, Regulatory Affairs

Brittany Avin McKelvey serves as the Director, Regulatory Affairs at Friends of Cancer Research (Friends). Friends is an advocacy organization based in Washington, DC that drives collaboration among partners from every healthcare sector to power advances in science, policy, and regulation that speed life-saving treatments to patients. For more than two decades, Friends has been instrumental in the creation and implementation of policies ensuring patients receive the best treatments in the fastest and safest way possible.

At Friends, Brittany supports the development and implementation of the organization’s research and policy agenda. Brittany leverages her patient advocacy and scientific background to generate scientific evidence and policies to advance progress in oncology care. She collaborates with diverse stakeholders to inform policy objectives and execute evidence-based research projects.

Prior to joining Friends, Brittany worked for the American Cancer Society Cancer Action Network (ACS CAN) as a Policy Fellow. As a Policy Fellow, Brittany conducted policy and legislative research and analysis to support ACS CAN’s advocacy agenda. She oversaw and guided a pilot project to reduce barriers to cancer clinical trial enrollment for patients and utilized her scientific background to help develop regulatory facing projects.

As a childhood cancer survivor, Brittany is actively involved as a patient research advocate with multiple organizations, including the National Cancer Institute (NCI) as a member of the NCI Council of Research Advocates (NCRA). Brittany works to advance the patient’s perspective in all facets of cancer research. She has spoken nationally as a patient research advocate, as well as on Capitol Hill to advance cancer research.

Brittany received her PhD in molecular biology and genetics from Johns Hopkins University School of Medicine and was a recipient of a National Science Foundation Graduate Research Fellowship Program Award. Her research focused on understanding the role of mutations on carcinogenesis in thyroid cancer. While at Hopkins, Brittany was also the president of the Johns Hopkins Science Policy Group.